Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

15.76 +0.39 (+2.50%)
Streaming Delayed Price Updated: 9:59 AM EDT, Oct 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) Investors
From Law Offices of Howard G. Smith
Via Business Wire
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Amylyx Pharmaceuticals, Inc. (AMLX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
AMYLYX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options
From Faruqi & Faruqi LLP
Via GlobeNewswire
Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Amylyx Pharmaceuticals, Inc. (AMLX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Amylyx Pharmaceuticals, Inc. (AMLX) Stockholder Alert: Robbins LLP Reminds Stockholders of Amylyx Pharmaceuticals, Inc. Class Action
From Robbins LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Amylyx Pharmaceuticals, Inc. (AMLX) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX
From Kahn Swick & Foti, LLC
Via Business Wire
Lost Money in Amylyx Pharmaceuticals, Inc.? Gibbs Law Group Investigates Potential Securities Law Violations
From Gibbs Law Group
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) Investors
From Kirby McInerney LLP
Via Business Wire
Get Rich Quick With These 3 Biotech Stocks to Buy Now
The new cycle is coming your way to boost millionaire-making securities. Check out these three biotech stocks to buy. 
Via InvestorPlace
AMYLYX PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX
From Rosen Law Firm
Via Business Wire
AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
AMLX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
AMYLYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Amylyx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
AMLX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Amylyx Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
3 small-cap biotechs with potential breakthroughs in 2024
These small-cap biotech stocks feature large addressable markets combined with positive analyst sentiment and potential breakthroughs in 2024. 
Via MarketBeat
Topics Bankruptcy
3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024
There are several potential biotech breakthroughs likely to occur in 2024, and these three biotech stocks could see substantial gains 
Via InvestorPlace
3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024
These top-rated biotech stocks are going to be in high demand in January and in every other month in 2024. 
Via InvestorPlace
7 Healthcare Stocks Taking Medicine to the Next Level
With advances in technology potentially able to improve the human condition, these are the compelling healthcare stocks to consider. 
Via InvestorPlace
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Amylyx Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
2 Biotech Stocks With Huge Catalysts in 2024
Important clinical-trial readouts on the way could send these stocks soaring in early 2024. 
Via The Motley Fool
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.